FrancophonIA/ELRC3.0 huggingface dataset:
English: For patients switching from immediate-release nicotinic acid to Trevaclyn, therapy should be initiated at the 1,000 mg/20 mg dose and advanced to the 2,000 mg/40 mg maintenance dose after four weeks.
Maltese: Filkaż tal-pazjenti li jaqilbu minn aċidu nikotiniku ta' rilaxx immedjat għal Trevaclyn, it-terapija għandha tinbeda bid-doża ta' 1,000 mg/20 mg u tgħaddi għad-doża ta' manteniment ta' 2,000 mg/40 mg wara erba' ġimgħat.
English: Opaque PVC/Aclar blister with push-through aluminium lidding containing 14 modified-release tablets.
Maltese: Folja opaka tal-PVC/Aclar b'għeluq ta' l-aluminju push-through li fiha 14-il pillola li jerħu lmediċina.
English: • sweating
Maltese: Suffejra.
English: • you are taking simvastatin (a statin) or a medicine containing simvastatin and are Chinese.
Maltese: • jekk qed tieħu simvastatin (statin) jew mediċina li fiha simvastatin u inti Ċiniż/a.
English: Cases of overdose have been reported; the maximum dose of Trevaclyn taken was 5,000 mg/100 mg. All patients recovered without sequelae.
Maltese: Ġew irrappurtati każi ta' doża eċċessiva; l-akbar doża ta' Trevaclyn li ttieħdet kienet 5,000 mg/100 mg.
English: Psychiatric disorders
Maltese: Terapija konkomitanti
English: Package size bottle (HDPE)
Maltese: 14-il pilloli folji (HDPE)
English: Strength Pharmaceutical Form Route of administration
Maltese: Qawwa Għamla farmaċewtika
English: Invented name
Maltese: Daqs talpakkett
English: The full EPAR for Canigen L4 can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: Canigen L4 contains four types of inactivated (killed) Leptospira strains: L. interrogans serogroup Canicola serovar Portland-vere, L. interrogans serogroup Icterohaemorrhagiae serovar Copenhageni, L. interrogans serogroup Australis serovar Bratislava, L. kirschneri serogroup Grippotyphosa serovar Dadas.
Maltese: Canigen L4 fih erba' tipi ta' razez ta' Leptospira inattivati (maqtula): L. interrogans serogrupp Canicola serovar Portland-vere, L. interrogans serogrupp Icterohaemorrhagiae serovar Copenhageni, L. interrogans serogrupp Australis serovar Bratislava, L. kirschneri serogrupp Grippotyphosa serovar Dadas.
English: Canine leptospirosis vaccine (inactivated)
Maltese: Vaċċin tal-leptospirożi tal-klieb (inattivat)
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom high levels of maternally derived antibodies (special type of proteins, received from the mother in the milk, that help the body to fight infection), it is recommended that the first vaccination is given at nine weeks of age.
Maltese: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom injezzjoni tista' tingħata minn sitta sa disa' ġimgħat u t-tieni waħda erba' ġimgħat wara.
English: This will help protect them against leptospirosis.
Maltese: Dan jgħin jipproteġihom kontra l-leptospirożi.
English: A mild and temporary increase in body temperature (1°C or less) may occur for a few days after vaccination, with some puppies showing less activity and/or a reduced appetite.
Maltese: Jista' jkun hemm żieda ħafifa u temporanja fit-temperatura tal-ġisem ( 1 °C jew inqas) għal ftit jiem wara t-tilqima, b' xi wħud mill-ġriewi juru inqas attività u/jew tnaqqis fl-aptit.
English: This summary was last updated in May 2015.
Maltese: Dan is-sommarju ġie aġġornat l-aħħar f'Mejju 2015.
English: This is a summary of the European public assessment report (EPAR) for Canigen L4.
Maltese: Dan id-dokument huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Canigen L4.
English: An occasional temporary, acute (short-term) hypersensitivity (allergic) reaction may occur.
Maltese: Jista' jkun hemm reazzjoni okkażjonali ta' ipersensittività (allerġika) akuta (fuq perjodu ta' żmien qasir) u temporanja.
English: Canigen L4 is a vaccine.
Maltese: Canigen L4 huwa vaċċin.
English: In dogs, leptospirosis can cause bleeding, hepatitis (inflammation of the liver) and jaundice (yellowing of the skin and eyes) or nephritis (kidney inflammation).
Maltese: Fil-klieb, il-leptospirożżi fil-klieb tikkawża fsada, epatite (infjammazzjoni fil-fwied) u suffejra (sfurija fil-ġilda u flgħajnejn) jew nefritis (infezzjoni fil-kliewi).
English: The company that makes Nobivac L4 has agreed that its scientific data can be used for Canigen L4 (‘informed consent').
Maltese: Ilkumpanija li tipproduċi Nobivac L4 qablet li d-data xjentifika tagħha tista' tintuża għal Canigen L4 (“kunsens infurmat”).
English: Canigen L4 is a veterinary vaccine used to vaccinate dogs from six weeks of age to protect against leptospirosis caused by one of four specific types of Leptospira bacteria.
Maltese: Canigen L4 huwa vaċċin veterinarju użat biex ilaqqam klieb minn sitt ġimgħat ta' età biex jipproteġi kontra leptospirożi kkawżata minn wieħed minn erba' tipi speċifiċi ta' batterji tal-Leptospira.
English: The bacteria are spread via the urine of infected animals.
Maltese: Il-batterji jinfirxu permezz tal-awrina ta' annimali infettati.
English: This vaccine is the same as Nobivac L4, which is already authorised in the European Union (EU).
Maltese: Dan il-vaċċin huwa l-istess bħal Nobivac L4, li diġà huwa awtorizzat fl-Unjoni Ewropea (UE).
English: Why is Canigen L4 approved?
Maltese: Għal xiex ġie approvat Canigen L4?
English: The European Commission granted a marketing authorisation valid throughout the EU for Canigen L4 on 3 July 2015.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq għal Canigen L4 valida fl-Unjoni Ewropea kollha fit-03/07/2015.
English: What are the risks associated with Canigen L4?
Maltese: X'inhuma r-riskji assoċjati ma' Canigen L4?
English: The strains of Leptospira bacteria in Canigen L4 are killed (inactivated) so that they do not cause disease.
Maltese: Ir-razez tal-batterji ta' Leptospira f'Canigen L4 jinqatlu (jiġu inattivati) sabiex ma jikkawżawx il-marda.
English: The medicine is available as tablets (10, 20 and 30 mg).
Maltese: Il-mediċina hija disponibbli bħala pilloli (10, 20 and 30 mg).
English: The full EPAR and risk management plan summary for Otezla can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Otezla contains the active substance apremilast.
Maltese: Otezla fih is-sustanza attiva apremilast.
English: This compared with 5% (15 of 282) and 6% (8 of 137) given placebo.
Maltese: Dan tqabbel ma' 5% (15 minn 282) u 6% (8 minn 137) li ngħataw plaċebo.
English: The active substance in Otezla, apremilast, blocks the action of an enzyme inside cells called phosphodiesterase 4 (PDE4).
Maltese: Is-sustanza attiva f'Otezla, apremilast, timblokka l-azzjoni ta' enzima ġewwa ċ-ċelloli msejħin phosphodiesterase 4 (PDE4).
English: This is a summary of the European public assessment report (EPAR) for Otezla.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Otezla.
English: Of the patients given Otezla in these two studies, 33% (168 of 562) and 29% (79 of 274) responded to treatment.
Maltese: Mill-pazjenti li ngħataw Otezla f'dawn iż-żewġ studji ewlenin, 33% (168 minn 562) u 29% (79 minn 274) taw rispons għall-kura.
English: Why is Otezla approved?
Maltese: Għaliex ġie approvat Otezla?
English: This was achieved in between 32 and 41% of patients given the approved dose of Otezla in the three studies, compared with 18 to 19% of those given placebo.
Maltese: Dan inkiseb f'bejn 32 u 41% tal-pazjenti li ngħataw id-doża approvata ta' Otezla fittliet studji, meta mqabbel ma' 18 sa 19% ta' dawk li ngħataw il-plaċebo.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Otezla on 15 January 2015.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal Otezla fil-15 ta' Jannar 2015.
English: For psoriatic arthritis, Otezla has been compared with placebo in 3 main studies, involving 1,493 patients with active disease despite prior treatment.
Maltese: Għal artrite psorjatika, Otezla tqabbel ma' plaċebo fi 3 studji ewlenin, li involvew 1,493 pazjent b'mard attiv minkejja kura minn qabel.
English: Response to treatment was defined as patients having a 75% or more reduction in a symptom score known as Psoriasis Area Severity Index (PASI-75).
Maltese: Ir-rispons għall-kura ġie definit bħala pazjenti li għandhom tnaqqis ta' 75% jew iktar filpunteġġ ta' sintomu magħruf bħala Indiċi tas-Severità taż-Żona tal-Psorajiżi (PASI-75).
English: In psoriasis, Otezla has been investigated in 2 main studies involving a total of 1,257 patients with moderate to severe plaque psoriasis, in which treatment with Otezla was compared with placebo (a dummy treatment).
Maltese: Fi psorajiżi, Otezla ġie investigat f'2 studji ewlenin li involvew total ta' 1,257 pazjent bi psorajiżi talplakka moderata sa severa, li fihom ġiet imqabbla l-kura b'Otezla ma' plaċebo (kura finta).
English: Other information about Otezla
Maltese: Informazzjoni oħra dwar Otezla
English: It is used in patients who have not responded to or cannot use other systemic (affecting the whole body) treatments for psoriasis, such as ciclosporin, methotrexate or PUVA (psoralen ultraviolet A).
Maltese: Jintuża f'pazjenti li ma tawx rispons għal jew li ma jistgħux jużaw kuri sistemiċi (li jaffetwaw ilġisem kollu) oħrajn għal psorajiżi, bħal ciclosporin, methotrexate jew PUVA (psoralen ultravjola A).
English: • active psoriatic arthritis (inflammation of the joints associated with psoriasis) in patients who cannot take or who have not responded well enough to other treatments called disease-modifying antirheumatic drugs (DMARDs).
Maltese: • artrite psorjatika attiva (infjammazzjoni tal-ġogi assoċjata ma' psorajiżi) f'pazjenti li ma jistgħux jieħdu jew li ma tawx rispons tajjeb biżżejjed għal kuri oħrajn imsejħin mediċini antirewmatiċi li jimmodifikaw il-marda (DMARDs).
English: For both psoriasis and psoriatic arthritis benefit there was evidence of maintained benefit when treatment was extended (to 32 and 52 weeks respectively).
Maltese: Kemm għall-benefiċċju f'psorajiżi kif ukoll f'artrite psorjatika kien hemm evidenza ta' benefiċċju miżmum meta l-kura ġiet estiża (għal 32 u 52 ġimgħa rispettivament).
English: The CHMP considered that benefit had been shown in psoriasis and psoriatic arthritis.
Maltese: Is-CHMP ikkunsidra li lbenefiċċju ntwera fi psoraijiżi u f'artrite psorjatika.
English: This enzyme plays a role in triggering the production of messenger molecules in the immune system (the body's natural defences) called cytokines, which are involved in the inflammation and other processes that cause psoriasis and psoriatic arthritis.
Maltese: Din l-enzima għandha rwol fl-iskattar tal-produzzjoni ta' molekuli messaġġiera fis-sistema immunitarja (id-difiżi naturali tal-ġisem) imsejħin ċirokini, li huma involuti flinfjammazzjoni u fi proċessi oħrajn li jikkawżaw psorajiżi u artrite psorjatika.
English: Although the medicine had not been compared with other authorised treatments, and for psoriatic arthritis X-ray evidence of an effect on the progress of the disease was not available, the mostly mild or moderate side effects and the fact that the medicine could be taken by mouth might make it more acceptable to patients.
Maltese: Għalkemm il-mediċina ma tqabblitx ma' kuri awtorizzati oħrajn, u ma kienx hemm evidenza b'X-ray ta' artrite psorjatika ta' effett fuq il progress tal-marda, l-effetti sekondarji ġeneralment ħfief jew moderati u l-fatt li l-mediċina tista' tittieħed millħalq jistgħu jagħmluha iktar aċċettabbli għall-pazjenti.
English: Treatment is started with a dose of 10 mg on day 1 and gradually increased over a week to the recommended dose of 30 mg twice a day.
Maltese: Il-kura tinbeda b'doża ta' 10 mg fl-1 jum u tiżdied bil-mod fuq medda ta' ġimgħa għad-doża rakkomandata ta' 30 mg darbtejn kuljum.
English: • moderate to severe plaque psoriasis (a disease causing red, scaly patches on the skin).
Maltese: • psorajiżi tal-plakka moderata sa severa (marda li tikkawża rqajja' ħomor bil-qxur fuq il-ġilda).
English: What are the risks associated with Otezla?
Maltese: X'inhuma r-riskji assoċjati ma' Otezla?
English: For the full list of all side effects and restrictions with Otezla, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji u restrizzjonijiet kollha b'Otezla, ara l-fuljett ta' tagħrif.
English: Otezla is a medicine used to treat adults with:
Maltese: Otezla huwa mediċina li tintuża fil-kura ta' adulti bi:
English: PUVA is a type of treatment where the patient receives a medicine containing a compound called a ‘psoralen' before being exposed to ultraviolet light.
Maltese: PUVA hija tip ta' kura fejn il-pazjent jirċievi mediċina li fiha kompost imsejjaħ ‘psoralen' qabel jiġi espost għal dawl ultravjola.
English: How is Otezla used?
Maltese: Kif jintuża Otezla?
English: The main measure of effectiveness was a 20% improvement in a score measuring symptoms such as tender and swollen joints (ACR-20) after 16 weeks of treatment.
Maltese: Il-kejl ewlieni taleffikaċja kien titjib ta' 20% f'punteġġ li jkejjel sintomi bħal ġogi rotob u minfuħin (ACR-20) wara 16-il ġimgħa ta' kura.
English: The most common side effects with Otezla (which may affect more than 1 in 10 people) are effects on the digestive system such as diarrhoea and nausea (feeling sick).
Maltese: L-effetti sekondarji l-aktar komuni b'Otezla (li jistgħu jaffettwaw aktar minn persuna 1 minn kull 10) huma effetti fuq is-sistema diġestiva bħal dijarea u dardir (tħossok ma tiflaħx).
English: By blocking PDE4, apremilast reduces the level of these cytokines in the body, and so reduces the inflammation and other symptoms of psoriasis and psoriatic arthritis.
Maltese: Billi jimblokka PDE4, apremilast inaqqas il-livell ta' dawn iċ-ċitokini fil-ġisem, u b'hekk inaqqas l-infjammazzjoni u sintomi oħrajn ta' psorajiżi u artrite psorjatika.
English: Patients who were already taking other so-called ‘small-molecule DMARDs' such as the medicine methotrexate continued this treatment during the study.
Maltese: Pazjenti li diġà kienu qed jieħdu hekk imsejħa ‘DMARDs b'molekuli żgħar' oħrajn bħall-mediċina methotrexate komplew din il-kura waqt l-istudju.
English: The other common side effects (which may affect up to 1 in 10 people) are upper respiratory tract infections (colds) and headaches or tension headaches.
Maltese: L-effetti sekondarji l-aktar komuni oħrajn (li jistgħu jaffettwaw sa persuna 1 minn kull 10) huma infezzjonijiet fil-parti ta' fuq tal-passaġġ respiratorju (irjiħat) u uġigħ ta' ras jew uġigħ ta' ras minħabba tensjoni.
English: A risk management plan has been developed to ensure that Otezla is used as safely as possible.
Maltese: Ġie żviluppat pjan ta' ġestjoni tar-riskju biex jiġi żgurat li Otezla jintuża bl-aktar mod sigur possibbli.
English: • regular contractions lasting at least 30 seconds at a rate of at least four every 30 minutes;
Maltese: • kontrazzjonijiet regolari li jdumu mill-inqas 30 sekonda b'rata ta' mill-inqas erbgħa kull 30 minuta;
English: The full EPAR for Atosiban SUN can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: It is given into a vein in three stages, over a maximum of 48 hours: an initial injection into a vein (6.75 mg), followed by a high-dose infusion (18 mg per hour) over three hours, then a lower dose infusion (6 mg per hour) lasting up to 45 hours.
Maltese: Jingħata fil-vina fi tliet fażijiet, fi żmien massimu ta' 48 siegħa: injezzjoni inizjali fil-vina (6.75 mg), segwita minn infużjoni b'dożaġġ qawwi (18 mg kull siegħa) tul tliet sigħat, imbagħad infużjoni b'dożaġġ aktar baxx (6mg kull siegħa) li ddum mhux aktar minn 45 siegħa.
English: • dilation of the cervix (the neck of the womb) of 1 to 3 cm and an effacement (a measure of the thinness of the cervix) of 50% or more.
Maltese: • twessigħ ċervikali (l-għonq tal-utru) ta' 1 sa 3 ċm u traqqiq tal-għonq tal-utru (tnaqqis tal-wisa' tal-għonq tal-utru) ta' 50% jew aktar.
English: The active substance in Atosiban SUN, atosiban, is an antagonist of the natural hormone oxytocin.
Maltese: Is-sustanza attiva f'Atosiban SUN, l-atosiban, hija antagonista tal-ormon naturali l-ossitoċina.
English: The CHMP concluded that, in accordance with EU requirements, Atosiban SUN has been shown to have comparable quality and to be comparable to Tractocile.
Maltese: Is-CHMP ikkonkluda li, b'konformità mar-rekwiżiti tal-UE, intwera li Atosiban SUN għandu kwalità komparabbli u huwa komparabbli għal Tractocile.
English: The company provided data from the published literature on atosiban.
Maltese: Il-kumpanija pprovdiet dejta minn letteratura ppubblikata dwar l-atosiban.
English: A risk management plan has been developed to ensure that Atosiban SUN is used as safely as possible.
Maltese: Ġie żviluppat pjan ta' ġestjoni tar-riskju biex jassigura li Atosiban SUN jintuża bl-aktar mod sigur possibbli.
English: In addition, the baby must have a normal heart rate.
Maltese: Barra minn hekk, it-tarbija għandu jkollha ritmu kardijaku normali.
English: This means that Atosiban SUN is similar to a ‘reference medicine' already authorised in the European Union (EU) called Tractocile.
Maltese: Atosiban SUN huwa ‘mediċina ġenerika' Dan ifisser li Atosiban SUN huwa simili għal ‘mediċina ta' referenza' diġà awtorizzata fl-Unjoni Ewropea (UE) bl-isem Tractocile.
English: How is Atosiban SUN used?
Maltese: Kif jintuża Atosiban SUN?
English: This is a summary of the European public assessment report (EPAR) for Atosiban SUN.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Atosiban SUN.
English: Because Atosiban SUN is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Maltese: Peress li Atosiban SUN huwa mediċina ġenerika, il-benefiċċji u r-riskji tiegħu huma meqjusa l-istess bħal dawk tal-mediċina ta' referenza.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Atosiban SUN on 31 July 2013.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal Atosiban SUN fil-31 ta' Lulju 2013.
English: It is used to delay birth in adult women who are 24 to 33 weeks pregnant, when they show signs that they may give birth preterm (prematurely).
Maltese: Jintuża biex jittardja t-twelid f'nisa ta' bejn l-24 u 33 ġimgħa ta' tqala, meta juru sinjali li jistgħu jwelldu qabel jagħlqilhom iż-żmien (prematur).
English: No additional studies were needed as Atosiban SUN is a generic medicine that is given by infusion or injection and contains the same active substance as the reference medicine, Tractocile.
Maltese: Ma kien jinħtieġ l-ebda studju addizzjonali peress li Atosiban SUN huwa mediċina ġenerika mogħtija permezz ta' infużjoni jew injezzjoni u fih l-istess sustanza attiva bħal dik tal-mediċina ta' referenza, Tractocile.
English: Atosiban SUN is a ‘generic medicine'.
Maltese: Atosiban SUN jista' jinkiseb biss b'riċetta ta' tabib.
English: By blocking the action of oxytocin, Atosiban SUN prevents contractions and causes the womb to relax, helping to delay birth.
Maltese: Billi jimblokka l-azzjoni tal-ossitoċina, Atosiban SUN jimpedixxi lkontrazzjonijiet u jikkawża r-rilassament tal-ġuf u b'hekk jittardja t-twelid.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Atosiban SUN, including the appropriate precautions to be followed by healthcare professionals and patients.
Maltese: Abbażi ta' dan il-pjan, fis-sommarju tal-karatteristiċ tal-prodott u l-fuljett ta' tagħrif ġiet inkluża informazzoni rigward is-sigurtà għal Atosiban SUN, inkluż il-prekawzjonijiet xierqa li għandhom jiġu segwiti mill-professjonisti tal-kura tas-saħħa u l-pazjenti.
English: Atosiban SUN is a medicine that contains the active substance atosiban.
Maltese: Dan ifisser li l-atosiban timblokka l-azzjoni tal-ossitoċina.
English: What are the benefits and risks of Atosiban SUN?
Maltese: X'inhuma l-benefiċċji u r-riskji ta' Atosiban SUN?
English: For more information on generic medicines, see the question-and-answer document here.
Maltese: Għal aktar tagħrif dwar ilmediċini ġeneriċi, ara d-dokument mistoqsijiet-u-tweġibiet hawnhekk.
English: It is not intended to provide practical advice on how to use Atosiban SUN.
Maltese: Dan mhux intiż biex jipprovdi konsultazzjoni prattika dwar kif jintuża Atosiban SUN.
English: The full EPAR for Stronghold Plus can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: Stronghold Plus selamectin / sarolaner
Maltese: Stronghold Plus selamektin / sarolaner
English: This summary was last updated in December 2016.
Maltese: Dan is-sommarju ġie aġġornat l-aħħar f'Diċembru 2016.
English: The European Commission granted a marketing authorisation valid throughout the EU for Stronghold Plus on 9 February 2017.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-UE kollha għal Stronghold Plus fid-9 ta' Frar 2017.
English: This is a summary of the European public assessment report (EPAR) for Stronghold Plus.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Stronghold Plus.
English: Other information about Stronghold Plus
Maltese: Informazzjoni oħra dwar Stronghold Plus
English: Selamectin and sarolaner are antiparasitic medicines.
Maltese: Is-selamektin u s-sarolaner huma mediċini kontra l-parassiti.
English: Stronghold Plus contains two active substances, selamectin and sarolaner.
Maltese: Stronghold Plus fih żewġ sustanzi attivi, selamektin u sarolaner.
English: Sarolaner blocks the normal movement of charged chloride particles in and out of nerve cells, especially those associated with gamma-aminobutyric acid (GABA) and glutamate, two substances that convey messages between nerves (neurotransmitters).
Maltese: Is-sarolaner timblokka l-moviment normali tal-partikoli ċċarġjati tal-kloru ġewwa u barra ċ-ċelloli tan-nervituri, speċjalment dawk assoċjati ma' aċidu gamma-aminobutirriku (GABA, gamma-aminobutyric acid) u ma' glutamat, żewġ sustanzi li jgħaddu l-messaġġi bejn in-nervituri (newrotrażmettituri).
English: Selamectin is effective against fleas, ear mites, biting lice, heartworms, roundworms and hookworms.
Maltese: Is-selamektin hi effettiva kontra l-briegħed, il-mites tal-widnejn, il-qamel li jigdem, il-heartworms, il-ħniex tondi u l-hookworms.
English: Two laboratory studies with cats artificially infested with ear mites showed Stronghold Plus to reduce ear mites by more than 90% 30 days after a single treatment.
Maltese: Żewġ studji fil-laboratorju bi qtates li ġew infestati b'mod artifiċjali bil-mites tal-widnejn urew li Stronghold Plus inaqqas il-mites tal-widnejn b'aktar minn 90 % 30 jum wara kura waħda.
English: Stronghold Plus was as effective as the other medicine and reduced tick counts by more than 90%.
Maltese: Stronghold Plus kien effettiv daqs il-mediċina l-oħra u naqqas l-għadd ta' qurdien b'aktar minn 90 %.
English: Two laboratory studies were conducted in cats with intestinal worms which showed Stronghold Plus to have more than 94% efficacy.
Maltese: Saru żewġ studji fil-laboratorji fi qtates b'dud intestinali li wrew li Stronghold Plus għandu effikaċja ta' aktar minn 94 %.
English: Selamectin activates special proteins called ‘chloride channels' on the surface of nerve and muscle cells of the parasite, allowing charged chloride particles to enter nerve cells and disrupting their normal electrical activity.
Maltese: Is-selamektin tattiva proteini speċjali msejħa “kanali tal-kloru” fuq il-wiċċ taċ-ċelloli tan-nervituri u tal-muskoli tal-parassit u b'hekk tippermetti l-partikoli ċċarġjati tal-kloru jidħlu fiċ-ċelloli tan-nervituri u jfixklu l-attività elettrika normali tagħhom.